Home › Companies › Bicara Therapeutics Inc. › 2025-2026
At Bicara Therapeutics Inc.'s shareholder meeting held June 9, 2026, in the 2025-2026 proxy season, 49 asset managers reported how they voted on 3 ballot items in their SEC Form N-PX filings, covering 496 separate fund positions. On the most widely held item on that ballot — To elect two class II directors to our board of directors, to serve until the 2029 annual… — Bicara Therapeutics Inc.'s filing reports the nominee as elected, with 88% support of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Bicara Therapeutics Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Bicara Therapeutics Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 9, 2026: 3 items on Bicara Therapeutics Inc.’s Form 8-K, filed June 10, 2026: 2 elected · 1 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Bicara Therapeutics Inc. in the interactive database Compare manager voting policies
These tallies are Bicara Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Christopher Bowden, M.D. | 48,558,710 | -- | -- | 5,145,418 | 2,220,859 | 90% | Elected | — |
| Elect Director: Carolyn Ng, Ph.D. | 47,431,269 | -- | -- | 6,272,859 | 2,220,859 | 88% | Elected | — |
| 2. Ratification of KPMG LLP | 55,914,602 | 8,815 | 1,570 | -- | -- | 99.9% | Approved | — |
Source: Bicara Therapeutics Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.
Each item below shows how the 49 asset managers that disclosed a Bicara Therapeutics Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Carolyn Ng, Ph.D.
Bicara Therapeutics Inc.’s own tally for this item (“Elect Director: Carolyn Ng, Ph.D.”): 47,431,269 for, 6,272,859 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected each of the following individuals to serve as class II directors for a three-year term ending at the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or…”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 11,088,126 for, 998,233 withheld, 7 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 5,136,968 | 0 | 0 | 0 | For |
| Vanguard | 2,044,465 | 0 | 7 | 0 | For |
| Fidelity | 1,137,914 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 881,690 | 0 | 0 | 0 | For |
| State Street | 1,430 | 0 | 0 | 700,907 | Withhold |
| BlackRock | 690,060 | 0 | 0 | 0 | For |
| Legg Mason | 275,000 | 0 | 0 | 0 | For |
| Charles Schwab | 264,275 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 227,016 | 0 | 0 | 0 | For |
| JPMorgan | 81,469 | 0 | 0 | 0 | For |
| Equitable | 35,624 | 0 | 0 | 24,300 | Mixed |
| Brighthouse | 45,091 | 0 | 0 | 11,639 | Mixed |
| American Century | 0 | 0 | 0 | 51,839 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 51,580 | Withhold |
| Lincoln Financial | 6,726 | 0 | 0 | 41,093 | Mixed |
| Northwestern Mutual | 46,771 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 37,282 | Withhold |
| John Hancock | 26,410 | 0 | 0 | 8,546 | Mixed |
| TIAA | 33,573 | 0 | 0 | 0 | For |
| Prudential/PGIM | 31,000 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 27,534 | Withhold |
| Advisor Managed Portfolios | 23,996 | 0 | 0 | 0 | For |
| Transamerica | 19,100 | 0 | 0 | 0 | For |
| Global X | 14,780 | 0 | 0 | 0 | For |
| Northern Trust | 14,729 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Christopher Bowden, M.D.
Bicara Therapeutics Inc.’s own tally for this item (“Elect Director: Christopher Bowden, M.D.”): 48,558,710 for, 5,145,418 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected each of the following individuals to serve as class II directors for a three-year term ending at the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 11,811,880 for, 274,478 withheld, 7 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 5,136,968 | 0 | 0 | 0 | For |
| Vanguard | 2,044,465 | 0 | 7 | 0 | For |
| Fidelity | 1,137,914 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 881,690 | 0 | 0 | 0 | For |
| State Street | 701,503 | 0 | 0 | 834 | For |
| BlackRock | 690,060 | 0 | 0 | 0 | For |
| Legg Mason | 275,000 | 0 | 0 | 0 | For |
| Charles Schwab | 264,275 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 227,016 | 0 | 0 | 0 | For |
| JPMorgan | 81,469 | 0 | 0 | 0 | For |
| Equitable | 35,624 | 0 | 0 | 24,300 | Mixed |
| Brighthouse | 45,091 | 0 | 0 | 11,639 | Mixed |
| American Century | 0 | 0 | 0 | 51,839 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 51,580 | Withhold |
| Lincoln Financial | 28,826 | 0 | 0 | 18,993 | Mixed |
| Northwestern Mutual | 46,771 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 37,282 | Withhold |
| John Hancock | 26,410 | 0 | 0 | 8,546 | Mixed |
| TIAA | 33,573 | 0 | 0 | 0 | For |
| Prudential/PGIM | 31,000 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 27,534 | Withhold |
| Advisor Managed Portfolios | 23,996 | 0 | 0 | 0 | For |
| Transamerica | 19,100 | 0 | 0 | 0 | For |
| Global X | 14,780 | 0 | 0 | 0 | For |
| Northern Trust | 14,729 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; and
Bicara Therapeutics Inc.’s own tally for this item (“2. Ratification of KPMG LLP”): 55,914,602 for, 8,815 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of KPMG LLP The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 12,086,365 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 5,136,968 | 0 | 0 | 0 | For |
| Vanguard | 2,044,472 | 0 | 0 | 0 | For |
| Fidelity | 1,137,914 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 881,690 | 0 | 0 | 0 | For |
| State Street | 702,337 | 0 | 0 | 0 | For |
| BlackRock | 690,060 | 0 | 0 | 0 | For |
| Legg Mason | 275,000 | 0 | 0 | 0 | For |
| Charles Schwab | 264,275 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 227,016 | 0 | 0 | 0 | For |
| JPMorgan | 81,469 | 0 | 0 | 0 | For |
| Equitable | 59,924 | 0 | 0 | 0 | For |
| Brighthouse | 56,730 | 0 | 0 | 0 | For |
| American Century | 51,839 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 51,580 | 0 | 0 | 0 | For |
| Lincoln Financial | 47,819 | 0 | 0 | 0 | For |
| Northwestern Mutual | 46,771 | 0 | 0 | 0 | For |
| Dimensional | 37,282 | 0 | 0 | 0 | For |
| John Hancock | 34,956 | 0 | 0 | 0 | For |
| TIAA | 33,573 | 0 | 0 | 0 | For |
| Prudential/PGIM | 31,000 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 27,534 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 23,996 | 0 | 0 | 0 | For |
| Transamerica | 19,100 | 0 | 0 | 0 | For |
| Global X | 14,780 | 0 | 0 | 0 | For |
| Northern Trust | 14,729 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 65,703,866 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 7.82% |
| 2 | Vanguard | 3.11% |
| 3 | Fidelity | 1.73% |
| 4 | FRANKLIN STRATEGIC SERIES | 1.34% |
| 5 | State Street | 1.07% |
| 6 | BlackRock | 1.05% |
| 7 | Legg Mason | 0.42% |
| 8 | Charles Schwab | 0.40% |
| 9 | Columbia Threadneedle | 0.35% |
| 10 | JPMorgan | 0.12% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with RA Capital Management, L.P. | 11.12% | DEF14A |
| RA Capital Management, L.P. | 11.08% | 13D |
| Kiran Mazumdar-Shaw | 9.67% | DEF14A |
| Entities affiliated with Biocon Ltd | 8.41% | DEF14A |
| Vestal Point Capital, LP | 8.26% | 13G |
| Entities affiliated with Invus Public Equities, L.P. | 7.94% | DEF14A |
| Deep Track Capital, LP | 6.18% | 13G |
| JANUS HENDERSON GROUP PLC | 5.08% | 13G |
| Red Tree GP, LLC | 4.83% | 13G |
| BlackRock | 4.33% | 13F |
Percentages above are of 65,703,866 shares outstanding, as reported by Bicara Therapeutics Inc. on its Form 10-Q dated May 5, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Bicara Therapeutics Inc.’s 10-Q dated May 5, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Bicara Therapeutics Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Bicara Therapeutics (BCAX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/bicara-therapeutics-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.